When my son had a huge boil under his arm, it turned out that it was filled with the killer staph, MRSA. It also turns out that my (otherwise) great doctor used a traditional lab to process the test, which took a week to determine it was MRSA.
Cepheid (NASDAQ: CPHD) manufactures the equipment and test that takes just two hours to do the same thing -- and is better and cheaper than traditional tests. CPHD wins 90%-plus of all competitive bids and its test could be available in low-tech facilities, such as doctor's offices or nursing homes, next year.
The big catalyst for this stock, however, is that Medicare will stop paying for all hospital-acquired infections except MRSA in October. So institutions need a quick test if they are going to be reimbursed for treatment.
The stock has fallen from $30 to under $9. It's worth $20 - $22 to an acquirer.
Your best strategy for life-changing profits?
Buy the call options.
Next: Biotech Stock #4
Prudential Earnings Preview: Strong 2009 Results Expected
Allstate Earnings Preview: Looking for a Turnaround
Disney Starts Off the New Fiscal Year with Solid Results
